THE EFFICIENCY FRONTIER APPROACH TO ECONOMIC EVALUATION OF HEALTH-CARE INTERVENTIONS
THE EFFICIENCY FRONTIER APPROACH TO ECONOMIC EVALUATION OF HEALTH-CARE INTERVENTIONS
复制标题
DOI：
10.1002/hec.1629
复制
发表时间：
2010-10-01
期刊：
影响因子：
2.1
通讯作者：
Kolominsky-Rabas, Peter
中科院分区：
文献类型：
--
作者：
Caro, J. Jaime;Nord, Erik;Kolominsky-Rabas, Peter
背景：IQWiG 委托一个国际专家小组开发评估德国法定医疗保健系统中效益与成本关系的方法。拟议方法：专家组建议 IQWiG 向德国决策者通报某项干预措施在该适应症的相关其他干预措施中的净成本和额外效益的价值。为了便于指导有关最大报销的指导，该信息以效率图的形式呈现，横轴为成本，纵轴为效益价值。效率边界将不占主导地位的干预措施联系起来并提供指导。一项位于前沿或左侧的技术是相当有效的，而一项位于右侧的技术则需要进一步证明以该价格进行补偿的合理性。此信息不会自动给出最大报销额，因为其他考虑因素可能相关。鉴于这些估计是针对特定适应症的，因此它们不涉及整个医疗保健系统的优先级设置。结论：这种方法可以让决策者了解干预措施的效率，符合任务规定，并且符合基本经济原则。需要对其可行性和有用性进行实证检验。版权所有 (C) 2010 约翰·威利父子有限公司
Background: IQWiG commissioned an international panel of experts to develop methods for the assessment of the relation of benefits to costs in the German statutory health-care system.Proposed methods: The panel recommended that IQWiG inform German decision makers of the net costs and value of additional benefits of an intervention in the context of relevant other interventions in that indication. To facilitate guidance regarding maximum reimbursement, this information is presented in an efficiency plot with costs on the horizontal axis and value of benefits on the vertical. The efficiency frontier links the interventions that are not dominated and provides guidance. A technology that places on the frontier or to the left is reasonably efficient, while one falling to the right requires further justification for reimbursement at that price. This information does not automatically give the maximum reimbursement, as other considerations may be relevant. Given that the estimates are for a specific indication, they do not address priority setting across the health-care system.Conclusion: This approach informs decision makers about efficiency of interventions, conforms to the mandate and is consistent with basic economic principles. Empirical testing of its feasibility and usefulness is required. Copyright (C) 2010 John Wiley & Sons, Ltd.